氯噻酮(Chlorthalidone) - 药物靶点：NCC_在研适应症：尿崩症，水肿，肾石病_专利_临床

概要

基本信息

简介氯噻酮是一种小分子药物，通过抑制负责肾脏中钠和氯化物重吸收的NCC蛋白起作用。这种药物是治疗尿崩症、高血压、肾结石和水肿的有用工具。赛诺菲是一家制药公司，于1959年率先开发并获得氯噻酮使用批准。作为一种利尿药物，氯噻酮通常用于通过增加尿液量和减少体内液体量来控制高血压。它在治疗一系列疾病方面的有效性，加上其悠久的历史，使其成为医疗领域的一种有价值的药物。

药物类型

小分子化药

别名

1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline、1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline、2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide

+ [16]

靶点

NCC

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

尿崩症水肿肾石病+ [1]

非在研适应症-

原研机构

在研机构

非在研机构

Sanofi-Aventis U.S. LLC

最高研发阶段批准上市

首次获批日期

瑞士 (1959-01-01),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C14H11ClN2O4S

InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N

CAS号77-36-1

关联

84

项与氯噻酮相关的临床试验

NCT02483936 / Not yet recruiting临床3期

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

开始日期2024-12-01

申办/合作机构

EMS Co. Ltd.

NCT02493322 / Not yet recruiting临床3期

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

开始日期2024-12-01

申办/合作机构

EMS Co. Ltd.

NCT06287580 / Not yet recruiting早期临床1期IIT

Antihypertensive Drug Effects on Cerebral Hemodynamics and Sympathetic Control in Older Hypertensive Patients

High blood pressure (BP) is a public health problem worldwide. Nearly three-quarters of older adults (age
60 years) in the United States have high BP. High BP links to many health problems, like stroke. Drug treatments are typically used in clinics to reduce high BP and the risk of associated health problems. However, these drug treatments may not always benefit brain health. For example, drug treatment may reduce brain blood flow, which may reduce cognitive function in older adults with high BP. Alternatively, reduced brain blood flow may cause high BP due to increased nervous system activity (the so-called "fight or flight response"). Thus, monitoring brain blood flow may help to manage high BP during drug treatment.
It is unknown if brain blood flow and its control will be altered by drug treatment in older high BP patients. Therefore, study team will recruit older adults with high BP, who receive either drug treatment or a placebo for 2 weeks and will assess brain blood flow, cognitive function, and nervous system control before and after treatment.
Results from this study will provide novel and clinically relevant information on the impact of drug treatment for high BP on brain health. Investigators expect these results will suggest that it is crucial to measure brain blood flow, which may be a therapeutic new target for BP control and brain health.

开始日期2024-05-15

申办/合作机构

The University of Texas Southwestern Medical Center

100 项与氯噻酮相关的临床结果

登录后查看更多信息

100 项与氯噻酮相关的转化医学

登录后查看更多信息

100 项与氯噻酮相关的专利（医药）

登录后查看更多信息

1,606

项与氯噻酮相关的文献（医药）

2024-03-01·Journal of hypertension

Use trends of chlorthalidone and hydrochlorothiazide among United States adults with hypertension: National Health and Nutrition Examination Survey 2009–2018

Article

作者: Perez, Alexandra ; El-Mcharfie, Layall ; Puchades, Emily ; Hale, Genevieve ; Jacomino, Gema

Objectives::

To estimate the national prevalence of chlorthalidone and hydrochlorothiazide use among adults diagnosed with hypertension by sociodemographic subgroup, healthcare access status, and clinical factors.

Methods::

Data was extracted from the National Health and Nutrition Examination Survey for 2009–2010 through 2017–2018 survey waves. Patients at least 20 years old, diagnosed with hypertension, and on hydrochlorothiazide or chlorthalidone were included. Uni-variable logistic regression models estimated the odds of being on chlorthalidone compared with hydrochlorothiazide use by sociodemographic and clinical factors. Analyses were adjusted for multi-stage complex survey design and are nationally representative.

Results::

Two thousand five hundred and eighty-five participants were included with 95.2% participants using hydrochlorothiazide and 4.8% using chlorthalidone. Participants over 65 years were more likely to be on chlorthalidone compared with younger counterparts [odds ratio (OR) 1.8; 95% confidence interval (CI) 1.12–2.88]. Participants with hypokalemia (OR 2.62; 95% CI 1.56–4.42) or hyponatremia [OR 2.298; 95% CI 1.23–4.30) were more likely to be using chlorthalidone compared with patients with normal levels.

Conclusion::

Chlorthalidone, a potent and effective first-line antihypertensive agent and thoroughly studied thiazide diuretic with substantial cardiovascular benefits, continues to be underutilized in patients with hypertension. Findings demonstrated that individuals receiving chlorthalidone were more likely to be 65 years or older and to experience hyponatremia or hypokalemia. Sociodemographic factors, healthcare access and use, clinical factors, and medical conditions did not appear to sway the choice in thiazide diuretic use.

2024-01-01·Hypertension (Dallas, Tex. : 1979)

Chlorthalidone or Spironolactone for Patients With TRH and Advanced Chronic Kidney Disease?

Article

作者: Auchus, Richard J ; Pitt, Bertram

2024-01-01·Annales pharmaceutiques francaises

Separation and quantification of azelnidipine and chlorthalidone in a synthetic mixture using optimized HPTLC method

Article

作者: Raimalani, Juhi ; Kotadiya, Rajendra

OBJECTIVES:

A simple, accurate, and reliable high-performance thin-layer chromatographic technique has been developed and validated for the simultaneous quantitation of azelnidipine and chlorthalidone in bulk and synthetic mixtures.

MATERIAL AND METHODS:

The procedure was carried out using a precoated silica gel 60 F254 TLC plate with a mobile phase of chloroform, ethyl acetate, and methanol in the ratio of 6.5:3.5:0.6 (by volume). Thin-layer chromatographic densitometry at 240nm was used to quantify medicines chromatographically.

RESULTS:

Over concentration ranges of 250.0 to 1000.0ng/band for chlorthalidone and 160.0 to 640.0ng/band for azelnidipine, the high-performance thin-layer chromatography technique was quantitated. This technique produced a tight and well-resolved band at retention factors of 0.67±0.02 and 0.24±0.02 for azelnidipine and chlorthalidone, respectively. Data from a linear regression study calibrating this method revealed a strong linear correlation between the two approaches, with regression coefficients of r2>0.99 for both. According to The International Conference for Harmonization of Technical Requirements for Pharmaceuticals for Human Use requirements, the procedures were validated for precision, robustness, accuracy, and specificity.

CONCLUSION:

The developed method was also used to simultaneously estimate azelnidipine and chlorthalidone in a synthetic mixture. The results were found to be in exemplary % assay with label claims.

7

项与氯噻酮相关的新闻（医药）

2024-05-16

·PRNewswire

New Analysis on Hypertension Treatment to be Presented as Late-Breaking Research at National Kidney Foundation Spring Clinical Meetings

LONG BEACH, Calif., May 16, 2024 /PRNewswire/ -- A new analysis of a study comparing two commonly used medications, chlorthalidone (CTD) and hydrochlorothiazide (HCTZ), is set to be presented as a late-breaking presentation at the annual 2024 National Kidney Foundation Spring Clinical Meetings. Continue Reading The study, titled "Treatment with Chlorthalidone vs Hydrochlorothiazide and Renal Outcomes: The Diuretic Comparison Project (DCP)," conducted by a team of distinguished researchers from various institutions and led by Areef Ishani, MD MS, Minneapolis VA Health Care System Primary Care and Specialty Care Integrated Care Community (ICC) Director and Professor of Medicine, University of Minnesota provides crucial insights into the impact of these medications on renal health in hypertensive patients. New study comparing two commonly used medications set to be shared as a late-breaking presentation at NKF's Conference. Post this Hypertension, or high blood pressure, is a significant risk factor for the development and progression of chronic kidney disease (CKD). Previous research had hinted at potential differences in kidney outcomes between chlorthalidone and hydrochlorothiazide. This new study followed more than 12,000 participants for an average of 3.9 years. The study found no significant disparity in renal outcomes between patients treated with chlorthalidone and those treated with hydrochlorothiazide. Specifically, there was no marked difference observed in the primary composite renal outcome, including doubling of serum creatinine, a significant drop in estimated glomerular filtration rate (eGFR), or kidney failure requiring treatment (KFRT), between the two treatment groups. Furthermore, the study revealed that the total slope of eGFR change and the incidence of chronic kidney disease (CKD) were comparable between patients receiving chlorthalidone and hydrochlorothiazide, suggesting similar efficacy in preserving kidney function. The findings offer reassurance that both chlorthalidone and hydrochlorothiazide may be equally effective choices for managing hypertension without compromising renal health. About NKF Spring Clinical Meetings For the past 32 years, nephrology healthcare professionals from across the country have come to NKF's Spring Clinical Meetings to learn about the newest developments related to all aspects of nephrology practice; network with colleagues; and present their research findings. The NKF Spring Clinical Meetings is designed for meaningful change in the multidisciplinary healthcare teams' skills, performance, and patient health outcomes. It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team. About Kidney Disease In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don't know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people. About NKF Professional Memberships Healthcare professionals can join NKF to receive access to tools and resources for both patients and professionals, discounts on professional education, and access to a network of thousands of individuals who treat patients with kidney disease. About the National Kidney Foundation The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. NKF Website Instagram Facebook X SOURCE The National Kidney Foundation

临床研究

2022-12-15

·Science Daily

New study method finds two blood pressure drugs equally effective

A clinical trial found that two first-line treatments for high blood pressure were equally effective. A large VA clinical trial found that the blood pressure drug chlorthalidone (CTD) was not superior to hydrochlorothiazide (HCTZ) for the prevention of cardiovascular disease or non-cancer death. Both drugs are in a class of medications called thiazide diuretics, commonly known as water pills. They are used to help the body rid itself of excess fluid, which can lower blood pressure. The study was a first-of-its-kind pragmatic trial that was embedded in usual clinical care. As part of VA's clinical trials enterprise, it allowed participation from across the country with no additional staff. Also, all study procedures were done as part of routine clinical care. There was no additional burden placed on Veterans who participated in the study, including no extra visits. "Because of the number of Veterans VA cares for and our systemwide electronic medical record, we were able to embed this massive clinical trial within day-to-day care without any additional burden to the thousands of Veterans who volunteered for this study," said Rachel Ramoni, VA's chief research and development officer. "The result is important evidence of how these widely-used medications work in the real world." Current clinical guidelines say that CTD may be more effective than HCTZ to lower blood pressure, but this recommendation is unsupported by direct evidence. Both medications have been used for more than 50 years and each is considered a first-line treatment for hypertension. "In 2020, Medicare reported that approximately 1.5 million people were prescribed CTD compared to 11.5 million prescribed HCTZ, despite guideline recommendations," said principal investigator Dr. Areef Ishani, director of the Minneapolis VA Health Care System's Primary Care and Specialty Care Integrated Care Community. "This discrepancy between clinical guidelines and real-world usage is possibly related to the belief that CTD has a greater risk of adverse effects without clear evidence for differences in cardiovascular outcomes." The Diuretic Comparison Project (CSP 597) is a large pragmatic clinical trial that was conducted at 537 VA medical centers and community clinics in the U.S. The trial enrolled more than 4,000 providers and 13,500 Veterans with high blood pressure who were taking HCTZ at baseline. Study participants were randomized to stay on their current dose of HCTZ or take an equivalent dose of CTD. Ninety-five percent of study participants were taking a lower dose of HCTZ, so the main study comparison was 12.5 mg CTD to 25 mg HCTZ. The team found no difference between the two drugs, at these lower doses, for the prevention of cardiovascular disease or non-cancer death, which included heart attack, stroke, heart failure, or lack of blood flow requiring medical intervention. There was a slight increase in the risk for low potassium in the CTD group, which quickly resolved with potassium supplements. "We were able to compare two commonly prescribed generic drugs using a low-cost methodology," said Ishani. "This trial has shown that large, embedded trials are operationally feasible. They can be incorporated into the clinical workflow of providers by leveraging the electronic health record and other existing infrastructure." The study was funded by the VA Cooperative Studies Program. The study results were published online December 14, 2022, by the New England Journal of Medicine.

临床结果AHA会议临床研究

2022-07-24

·丁香园

医生给高血压患者开氢氯噻嗪被医学生投诉！究竟谁错了？

近期在丁香园论坛闲逛，看到了这样一个病例：针对上述病例中的患者是否应该处方「氢氯噻嗪」，站友们的观点基本一致：「氢氯噻嗪确实会影响血糖和血尿酸，但是并没有禁用于这些情况，医生很多时候都是在权衡利弊。就算出现了副作用，血糖和尿酸也有其他调整的办法。而一旦停药导致患者血压控制不佳，甚至出现夹层、脑出血等严重并发症，后果不堪设想」。当然，医生确实也存在问题，应该提前告知患者用药的潜在风险，并做好定期复查。那么，临床中真的遇到这种情况究竟该怎么办呢？今天就给大家理一理。利尿剂该不该用？难治性高血压定义为在改善生活方式的基础上，应用了合理可耐受的足量 3 种或 3 种以上降压药物（包括利尿剂）一个月以上血压仍未达标，或服用 4 种或 4 种以上降压药物血压才能有效控制，称为难治性高血压。美国心脏协会曾发表「难治性高血压诊断、评估和治疗」的声明指出：未应用利尿剂或利尿剂剂量不足是导致难治性高血压的原因之一，增加利尿剂剂量是控制难治性高血压的主要手段。足以见其重要性。该患除利尿剂（氢氯噻嗪），已应用 3 种降压药（ARB、CCB、β 受体阻滞剂），若均已应用至合理可耐受的足量，血压控制仍欠佳，确实应加用利尿剂。用于控制血压的利尿剂主要是噻嗪类利尿剂，分为噻嗪型利尿剂和噻嗪样利尿剂两种，前者包括氢氯噻嗪和苄氟噻嗪等，后者包括氯噻酮和吲达帕胺等。此类药物尤其适用于老年高血压、单纯收缩期高血压或伴心力衰竭患者，也是难治性高血压的基础药物之一。小剂量噻嗪类利尿剂（如氢氯噻嗪 6.25～25 mg）对代谢的影响较小，不增加新发糖尿病的风险。其与 ACEI/ARB 联用，具有协同降压作用，利尿剂的不良反应减少，从而降低糖尿病患者的病死率和心血管病发生率。RAAS 抑制剂联合低剂量利尿剂的固定复方制剂也推荐用于高血压伴糖尿病的治疗。大剂量噻嗪类利尿剂或与 β 受体阻滞剂联用可能对糖脂代谢或电解质平衡有影响，不建议大剂量应用或二者联用。若必须联用，应结合患者情况，做好定期复查。合并高尿酸血症的患者应慎用利尿剂。做好定期复查。难治性高血压的药物选择1）需要联合 ≥ 3 种不同降压机制的药物，应选择长效或固定复方制剂以减少给药次数和片数。酌情将全天用药一次或分成早、晚服用，以控制全天血压。2）三药联合方案推荐 RAS 抑制剂 + CCB + 噻嗪类利尿剂，药物剂量应为常规或双倍的可耐受剂量。对于血钾＜ 4.5 mmol/L、eGFR ＞ 45 mL/（min · 1.73m²）的患者可以考虑使用螺内酯作为第 4 种药物。3）对高肾素及高交感患者以 RAS 抑制剂和 β 受体阻滞剂治疗为主；对醛固酮增多症患者，应加用螺内酯；对容量增高及循环 RAS 低下患者，以 CCB 和利尿剂为主。4）对摄盐量大或盐敏感患者，在强调严格限盐的同时适当增加噻嗪类利尿剂用量；对 eGFR ≤ 30 mL/（min · 1.73m²）的患者应采用袢利尿剂。非透析的肾功能不全患者由于 RAS 抑制剂的使用或剂量受限，应增加 CCB 的剂量，甚至将二氢吡啶类与非二氢吡啶类 CCB 合用，必要时联合 β 受体阻滞剂、α、β 受体阻滞剂或 α 受体阻滞剂。血压仍不能达标时可以考虑使用可乐定、利血平等中枢神经抑制药物。5）ARNI 是一种同时作用于 RAAS 和 NPs、增强 NPs 的血压调节作用同时抑制 RAAS 而实现多途径降压的新型药物。沙库巴曲缬沙坦可用于原发性高血压患者的降压治疗，常规剂量为 200 mg，1 次/d，对于难治性高血压患者可增至 300～400 mg/d。高龄老年人、伴有 HFrEF 的患者、合并 CKD 3～4 期的患者可从低剂量 50～100 mg/d 开始。如患者耐受，每 2～4 周将剂量加倍，以达到患者最适宜的剂量，实现血压控制以及耐受的平衡。策划：ly投稿：wangliya1@dxy.cn题图：站酷海洛参考文献：[1] 孙宁玲, 霍勇, 王继光, 等. 难治性高血压诊断治疗中国专家共识 [J]. 中国介入心脏病血杂志,2013,21(2):69-73.[2] 国家卫生计生委合理用药专家委员会，中国医师协会高血压专业委员会. 高血压合理用药指南 (第 2 版)[J]. 中国医学前沿杂志 (电子版),2017,9(7):28-121.[3] 中国高血压防治指南修订委员会, 高血压联盟 (中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南 (2018 年修订版)[J]. 中国心血管杂志,2019,24(1):24-55.[4] 中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议 [J]. 中华高血压杂志,2021,29(2):108-112.[5] Thomas Unger, Claudio Borghi, Fadi Charchar, et,al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines[J].J Hypertens,2020,38(6):982-1004.[6] 陈晓, 崔兆强, 林金秀, 等.2020 国际高血压学会全球高血压实践指南》解读 [J]. 中国医学前沿杂志 (电子版),2020,12(5):54-60.

100 项与氯噻酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00272	氯噻酮	C03BA04	DB00310

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
尿崩症	中国	成都第一制药有限公司	1985-01-01
水肿	中国	成都第一制药有限公司	1985-01-01
肾石病	中国	成都第一制药有限公司	1985-01-01
高血压	瑞士	Sanofi	1959-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02665117 (CTgov)	N/A	高血压	61	KMgCit+Potassium Magnesium Citrate (KMgCit)+chlorthalidone (KMgCit + Chlorthalidone)	糧製選窪齋製簾醖構鹹(鑰積觸顧膚糧鹽餘鹽範) = 獵窪範鹹鹹憲製艱壓淵淵壓網鏇艱窪製構壓廠 (選願繭網觸願鹹鹹鏇艱, 襯獵艱憲膚繭衊繭鏇鏇 ~ 襯觸顧選範網觸觸膚積) 更多	-	2023-10-25
				Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone)	糧製選窪齋製簾醖構鹹(鑰積觸顧膚糧鹽餘鹽範) = 積襯願獵範鹽蓋憲築蓋淵壓網鏇艱窪製構壓廠 (選願繭網觸願鹹鹹鏇艱, 範獵鹹構獵鑰襯餘齋窪 ~ 遞糧膚餘醖齋衊淵選壓) 更多
NCT02185417 (Pubmed \| Br Dent J)	临床3期	高血压	13,523	Chlorthalidone	窪願構鹹願構糧鑰醖餘(築齋廠憲觸遞簾齋顧襯) = The incidence of hypokalemia was higher in the chlorthalidone group than in the hydrochlorothiazide group (6.0% vs. 4.4%, P<0.001) 網積鹽獵鏇鹽鏇顧鹽壓 (夢製糧繭窪鬱夢繭繭築 ) 更多	不佳	2022-12-14
				Hydrochlorothiazide
NCT02841280 (CTgov)	临床2期	慢性肾病 \| 高血压	160	Chlorthalidone (Chlorthalidone)	簾淵襯憲鏇夢鑰構願窪(鑰範壓鏇醖夢窪範築構) = 壓襯鑰範鹹網觸淵艱蓋範衊憲餘鬱範積築積艱 (淵網齋憲艱製鏇選鬱構, 鏇製遞醖簾膚遞遞夢繭 ~ 積鹹醖範獵簾顧醖獵構) 更多	-	2022-03-31
				Placebo (Placebo)	簾淵襯憲鏇夢鑰構願窪(鑰範壓鏇醖夢窪範築構) = 夢醖網獵獵獵膚積襯築範衊憲餘鬱範積築積艱 (淵網齋憲艱製鏇選鬱構, 蓋製繭鬱顧夢鑰簾衊鑰 ~ 鑰簾鑰積餘網簾齋鏇夢) 更多
NCT02841280 (Pubmed) 人工标引	临床2期	高血压 \| 慢性肾病	160	Chlorthalidone	鑰壓鏇窪鏇醖廠糧顧顧(簾蓋壓壓選鏇觸廠膚憲) = 齋築鏇鑰鹹餘獵範鏇鑰鹹獵繭範範窪範構顧餘 (壓膚遞襯鬱簾餘齋齋製, -13.9 ~ -8.1)	积极	2021-11-05
				Placebo	鑰壓鏇窪鏇醖廠糧顧顧(簾蓋壓壓選鏇觸廠膚憲) = 願膚糧鏇齋膚窪齋鬱夢鹹獵繭範範窪範構顧餘 (壓膚遞襯鬱簾餘齋齋製, -3.5 ~ 2.5)
NCT03325114 (CTgov)	临床2期	高钙尿症 \| 1型糖尿病	1	chlorthalidone	夢艱簾蓋獵壓範願膚壓(鹽選獵醖觸鑰蓋餘構積) = 選遞醖繭繭網積窪憲齋遞顧觸選鹹襯鏇窪壓鑰 (遞壓鬱顧膚觸繭鹹獵艱, 遞願衊壓廠艱顧鑰獵範 ~ 簾觸壓夢襯鏇範餘願憲) 更多	-	2021-01-05
HEBE Trial (ASN2020)	临床4期	慢性肾病	-	Bumetanide 2 mg BID + Chlorthalidone 50 mg BID	鑰廠艱製窪夢壓築遞淵(憲蓋鹹範簾淵憲範餘廠) = 簾齋憲顧獵夢壓蓋鏇選艱廠願觸襯膚製齋鑰製 (憲遞鏇鏇襯憲淵廠積壓, 10.7) 更多	积极	2020-10-19
				Bumetanide 2 mg BID + Placebo	鑰廠艱製窪夢壓築遞淵(憲蓋鹹範簾淵憲範餘廠) = 簾積積廠鬱襯構淵鏇鏇艱廠願觸襯膚製齋鑰製 (憲遞鏇鏇襯憲淵廠積壓, 11.9) 更多
NCT04393493 (CTgov)	临床2期	心肾综合征	80	Furosemide (Stepped Furosemide)	蓋壓鏇構窪餘齋網網選(顧餘衊鏇糧鹽醖淵構顧) = 範選簾淵築鏇壓獵蓋夢餘構淵餘齋遞觸觸艱憲 (鹽鹽製齋築蓋繭艱鹽繭, 製餘鬱膚積鹹糧獵觸衊 ~ 繭襯艱範選製網齋簾獵) 更多	-	2020-09-14
				Spironolactone+Furosemide+Chlortalidone (Diuretics Combined)	蓋壓鏇構窪餘齋網網選(顧餘衊鏇糧鹽醖淵構顧) = 簾獵夢構簾鑰窪餘淵積餘構淵餘齋遞觸觸艱憲 (鹽鹽製齋築蓋繭艱鹽繭, 壓糧獵製簾範餘壓鏇衊 ~ 顧範憲艱齋鑰願衊衊齋) 更多
HEBE-CKD Trial (ESC2020)	N/A	慢性肾病	-	Bumetanide + Chlorthalidone	廠簾選繭鹽鑰鑰製鹽網(簾壓製鹹膚襯壓築憲築) = 顧鑰膚鹽繭夢範糧憲窪齋構衊顧壓齋構製構獵 (選構蓋製窪衊壓網鬱範 ) 更多	积极	2020-08-30
				Bumetanide + Placebo	廠簾選繭鹽鑰鑰製鹽網(簾壓製鹹膚襯壓築憲築) = 鑰積築壓範繭鹹築範夢齋構衊顧壓齋構製構獵 (選構蓋製窪衊壓網鬱範 ) 更多
NCT03923933 (CTgov)	临床2期	慢性肾病	34	Bumetanide (Placebo)	衊壓淵鏇壓遞簾鬱餘顧(選築獵艱艱齋衊鬱餘淵) = 衊淵築膚醖網範壓膚膚壓鹹遞築製齋鑰獵蓋蓋 (遞鏇鹹憲製餘膚繭鏇齋, 簾鏇積獵積網構艱鬱鑰 ~ 窪壓製鑰壓積夢鹹鬱鬱) 更多	-	2020-03-10
				Bumetanide+Chlorthalidone (Treatment Grup)	衊壓淵鏇壓遞簾鬱餘顧(選築獵艱艱齋衊鬱餘淵) = 製鏇壓觸觸網齋鬱簾選壓鹹遞築製齋鑰獵蓋蓋 (遞鏇鹹憲製餘膚繭鏇齋, 艱廠鑰鬱簾淵鑰範衊鹽 ~ 衊製膚糧壓觸壓廠製獵) 更多
NCT03000608 (CTgov)	临床2期	斑块状银屑病	69	S-amlodipine+Chlorthalidone (SAN021 Serum)	衊觸鬱製網鏇膚鹹觸顧(遞夢壓願選廠餘繭窪糧) = 窪範簾艱網壓憲餘鹽醖製顧鏇鑰鹹選襯製獵壓 (願鏇膚鑰糧醖願遞廠顧, 鹽鏇觸鏇糧鬱鬱選壓壓 ~ 築憲襯鑰願鏇選齋獵範) 更多	-	2019-05-29
				SAN021 Placebo (SAN021 Placebo)	衊觸鬱製網鏇膚鹹觸顧(遞夢壓願選廠餘繭窪糧) = 餘廠顧壓餘淵壓窪選觸製顧鏇鑰鹹選襯製獵壓 (願鏇膚鑰糧醖願遞廠顧, 膚夢壓憲壓鏇襯壓窪衊 ~ 襯製鬱鏇壓構築願餘製) 更多